Combination therapy facilitates optimal stem cell collection
Motixafortide plus standard stem cell therapy helped to “rapidly” mobilise stem cells in multiple myeloma, a Phase III trial has shown.
List view / Grid view
News
Merck to develop mAb through $10.8b acquisition
Through a $10.8 billion acquisition, Merck has agreed to buy Prometheus Biosciences to advance development of a novel monoclonal antibody for immune conditions.
Navigating delivery challenges of nucleic acid therapeutics
A paper has reviewed how novel drug delivery systems could achieve stable formulations of nucleic acid therapeutics.
Can automated buffer management systems overcome bioprocessing bottlenecks?
Researchers have developed a new automated buffer management system that offers supply to continuous downstream process for 10 days with consistent quality.
INTERPHEX 2023 – experience science through commercialisation
From development to distribution, leading global event Interphex 2023 (April 25-27 New York, US) takes you through all stages of the pharma product lifecycle.
Biogen to develop amyloid beta-targeting antibody platform
The next-generation of anti- amyloid beta therapeutics could be advanced by Biogen exercising the option to develop Denali’s antibody programme.
Personalised blood pressure treatment shows efficacy
A study suggests that personalised blood pressure medication can "probably obtain better protection against future cardiovascular diseases".
Microbial fermentation tech market to exceed $56.9b by 2033
Trends such as sustainability and technological advances like AI are helping to boost the microbial fermentation technology market, a report says.
A review of MALDI-TOF for microbiological identification
Rapid identification of well-known bacterial species makes MALDI-TOF mass spectrometry a suitable alternative to conventional systems, researchers have stated.
Sustained-release chemotherapy has potential for bladder cancer
A study has shown an intravesical sustained-release chemotherapy device demonstrated effectiveness in advanced bladder cancer.
NICE guidance recommends olaparib for breast and prostate cancers
PARP inhibitor olaparib has been recommended in NICE’s final draft guidance for early breast cancer and advanced prostate cancer.
Eculizumab biosimilar gets positive CHMP opinion
Samsung Bioepis’ first haematology biosimilar, which references Soliris (eculizumab), has been recommended for approval by the CHMP.
CGT supply chain and logistics market worth $3.12b by 2031
Improvements in real-time supply chain operations is expected to drive the cell and gene therapy supply chain/logistics market, a report says.
Could reducing agar concentration enhance microbial growth?
Improvements to the pour plate method during rapid microbial assessment could facilitate automation of the technique, according to research.
Monoclonal antibodies can lower COVID-19 hospitalisation risk
Over a third of COVID-19 patients reduced their risk of serious outcomes when treated early with monoclonal antibodies, a study shows.
